Format

Send to

Choose Destination
ISRN Ophthalmol. 2013 Dec 19;2013:141279. doi: 10.1155/2013/141279. eCollection 2013.

Comparison between Intravitreal Triamcinolone with Grid Laser Photocoagulation versus Bevacizumab with Grid Laser Photocoagulation Combinations for Branch Retinal Vein Occlusion.

Author information

1
Beyoglu Eye Training and Research Hospital, Bereketzade Camii Sok., Kuledibi, Beyoglu, 34421 Istanbul, Turkey.
2
Beyoglu Eye Training and Research Hospital, Bereketzade Camii Sok., Kuledibi, Beyoglu, 34421 Istanbul, Turkey ; Department of Ophthalmology, Medeniyet University, 34700 Istanbul, Turkey.

Abstract

PURPOSE:

To compare the efficacy of intravitreal triamcinolone (IVT) and intravitreal bevacizumab (IVB), both combined with grid laser photocoagulation (GLP) for macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

METHODS:

Retrospective, comparative study. The newly diagnosed patients with ME secondary to BRVO who were treated with IVT and GLP or IVB and GLP were included. The main outcome measures were changed in the best corrected visual acuity (BCVA) and central retinal thickness (CRT) from the baseline to month 24.

RESULTS:

Ninety-nine eyes of 99 patients were included. The change in BCVA was not statistically different in any time points between the two groups (P > 0.05, for all). The change in CRT was not statistically different in any time points between the two groups (P > 0.05, for all). The mean number of injections at month 24 was 2.38 ± 1.06 in the IVT+GLP group and 4.17 ± 1.30 in the IVB+GLP group (P = 0.0001). The need for cataract surgery (P = 0.01) and secondary glaucoma (P = 0.03) occurrence were more common in IVT group.

CONCLUSION:

Both treatment modalities were effective in the treatment of ME secondary to BRVO. The number of injections was significantly lower in the IVT group than in the IVB group; however cataract and secondary glaucoma were more frequent in the IVT+GLP group than in the IVB+GLP group.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center